*Promoted by Sica Media

📈 Join us for LIVE TRADING action all day long in the 📈

 Market Master’s trading room

All the action is heating right now, so let’s get to it!

Today’s hot new idea is NeuroOne Med (NMTC).

One of the best ways I know to find great trades is to identify broad trends that are showing up on social media.

It really can be one of the best tools you can use to find new hot ideas.

Over the years, I have found great times to buy Netflix (NFLX) because of a blockbuster show (remember the Squid Games hype?).

… Or, Lululemon (LULU) when certain clothes are selling out.

… I even recently had a great trade on Intuitive Machines (LUNR) as social media was captivated by them live-streaming a moon landing a few weeks ago.

Well, this week, you have probably heard about Neuralink (Elon’s company), which has just demonstrated the ability to let paralyzed patients actually control a screen and play games.

Maybe hundreds of millions of people have watched these videos over the last week and people are actively talking about it.

But guess what?  You can’t trade Neuralink.  It is a private company.

Where there is a lot of hype around a company like this, look for the spillover into other companies that might have a connection.

This company doesn’t do the same thing as Neuralink, but they are one of a handful of emerging neuroscience companies.

And that is what brings me to NeuroOne Medical (NMTC) today.

Sometimes, you just have the right stock at the right time people are searching.

I haven’t seen anyone else talk about it yet, but I am sure that I’m not the only one making this connection right now.

Just look at the chart of this normally “sleepy” little stock that trades around $1…

Sleepy little NMTC is waking up in a BIG way right now.  

A few weeks ago, you can see there was a pretty clear “Gamma Trigger” setup where the stock started to break above the 20-hour line + multiple “GO” signals fired.

That signal led to a 30% move over a few days.

You can see the same pattern setting up right now.  

In fact, the new signal just fired yesterday, and there was a flurry of trading activity, but not a huge breakout for the stock.

I think that makes this a PERFECT stock to focus on today.

Momentum started to move it higher yesterday, and I think today is the crucial “make or break” moment for NMTC.

If today is the breakout day, you better put on your big boy trading pants and get ready – it could be like a supernova. 💥

As you are doing your homework on NMTC today, here are some great points I have put together to help you…

NeuroOne Medical Technologies Corp (NMTC) is a medical technology developer of electrodes designed to diagnose and treat a variety of neurological conditions.

Despite being a relatively small company, NMTC has received FDA clearance for three of its devices and has forged powerful partnerships with the likes of the Mayo Clinic — the nation’s top-ranked hospital.

NMTC’s clinical partnership with the Mayo Clinic began in 2017, and the first commercial human use of one of NMTC’s electrodes was performed at the Mayo Clinic in November 2020.

Today, the Mayo Clinic is a top shareholder in NMTC, and its leading neurologist, Dr. Greg Worrell, chairs the company’s Scientific Advisory Board.

According to the company, this collaboration with the Mayo Clinic has produced “disruptive next-generation diagnostic electrodes advancing a new era in neuroscience.”

The company’s three FDA-cleared devices are:

Evo® Cortical Electrode – A device that can “monitor, record and stimulate the surface of the brain for up to 30 days.” It’s up to seven times thinner and eight times lighter than the legacy silicon-based electrodes.

These electrodes are designed to cause less trauma to the brain and therefore generate a decreased immune response, which can interfere with electrode readings.

Evo® sEEG Electrode – An advanced diagnostic device for seizure detection. It’s designed to be less invasive and to reduce the risk of “plunging” and brain damage.

The company says this electrode offers “proven placement accuracy and outstanding signal quality,” allowing doctors to “capture the vital data [they] need to support more confident diagnoses.”

OneRF™ Therapeutic Ablation Electrode System – This is a technology that pairs with the sEEG electrodes to provide therapeutic functionality in addition to the diagnostic.

Cleared by the FDA in December, this system creates radiofrequency (“RF”) lesions in nervous tissue for use in neurosurgical procedures.

NMTC formed a strategic partnership in July 2020 with Zimmer Biomet (ZBH, ~$25B market cap) — “a worldwide leader in robotic technology used in minimally invasive neurosurgeries” — to exclusively commercialize and distribute its EVO® diagnostic electrodes.

NMTC received a $2 million upfront payment through this partnership and a $3.5 million accelerated payment for reaching an agreed-upon milestone.

For its OneRF™ system, NMTC has already placed component orders for commercialization, and it expects to launch the product either directly or with a strategic partner in the first half of 2024. 

Now that it has reached the commercialization stage for its electrodes, NMTC’s revenues have climbed significantly, from $171,000 in FY 2022 to $1,952,000 for FY 2023.

Significantly, NMTC CFO Ronald McClurg made a big insider purchase of 50,900 shares of the company’s stock.

Spend time right now doing your own due diligence, and of course, always approach your trading in a responsible manner. Trading is very risky and nothing is ever guaranteed, so never trade with more than you can afford to lose, and always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom Line: We have a very time-sensitive situation with NMTC today. The stock is at a key inflection point, and I think it is either going to breakout (or down) from here. Because of yesterday’s surge and all the hype on social media, I think it is extremely important to keep NMTC at the top of your list today.

This will be a good learning experience for everyone.

To Your Success,

Jeff Bishop

👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!).  Don’t miss out!

*Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.



*PAID ADVERTISEMENT. Raging Bull has currently been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. for a one-day marketing program on march 26. 2024. Raging Bull was previously paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. for a one-day marketing program on march 4, 2024.  Raging Bull was previously paid five thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. from a period beginning on December 12 through December 12, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of NeuroOne Medical Technologies Corp., increased trading volume, and possibly an increased share price of NeuroOne Medical Technologies Corp.’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in NeuroOne Medical Technologies Corp., though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.

FOR COMMERCIAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for commercial and informational purposes only. A portion of our business is engaged in the promotion, marketing, and advertising of companies including public companies. A portion of Raging Bull’s business model is to receive financial compensation to promote public companies, conduct investor relations advertising and marketing, and publicly disseminate information regarding public companies through our websites email, SMS, and push notifications among other methods of communication. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. All material information contained in this advertisement is based on information generally available to the public, including information released to the public or filed by the Company with applicable regulators which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.  Never invest in any stock featured in this advertisement, on our site or emails unless you can afford to lose your entire investment. 

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. 

USE OF FORWARD-LOOKING STATEMENTS. Our advertisements including this advertisement and related emails, reports and alerts may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information in this advertisement, related emails, reports or alerts or on our website or media webpage. This information is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.  Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec .gov/edgar/searchedgar/company search

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.

WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.